Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis

Ataman, Şebnem; Sunar, İsmihan; Bodur, Hatice; Melikoğlu, Meltem Alkan; Çay, Hasan Fatih; Çapkın, Erhan; Akgül, Özgür; Çevik, Remzi; Göğüş, Feride; Kamanlı, Ayhan; Yurdakul, Fatma Gül; Gürer, Gülcan; Yağcı, İlker; Rezvanı, Aylin; Duruöz, Mehmet Tuncay

doi:10.1007/s40744-021-00403-y

Cited by 3 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The participant assessments were all performed on the same day at the Glasgow Caledonian University Human performance laboratory. Demographic and clinical information was collected, including age, sex, disease duration, DAS-28 ESR scores and current medication [ 18 , 19 ]. The modified version of the RA disease activity index (mRADAI-5) was collected as an additional self-reported measure of global disease activity [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

Assessing the construct validity of musculoskeletal ultrasound and the rheumatoid arthritis foot disease activity index (RADAI-F5) for managing rheumatoid foot disease

Hoque

Steultjens

Dickson

et al. 2023

Rheumatology Advances in Practice

View full text Add to dashboard Cite

Objectives The Rheumatoid Arthritis Foot Disease Activity Index (RADAI-F5) is a valid, reliable, and clinically feasible patient-reported outcome measure (PROM) for the measurement of rheumatoid arthritis (RA) foot disease activity. Further validation of the RADAI-F5 against musculoskeletal ultrasonography (MSUS) for foot disease activity are necessary prior to clinical implementation. This study aimed to examine the construct validity of the RADAI-F5 in relation to MSUS and clinical examination. Method Participants with RA completed the RADAI-F5. MSUS was employed to evaluate disease activity (synovial hypertrophy/synovitis/tenosynovitis/bursitis) and joint damage (erosion) utilising grayscale (GS) and power Doppler (PD) at 16 regions in each foot, including joints and soft tissues. These same regions were examined clinically for swelling and tenderness. The construct validity of the RADAI-F5 was assessed using correlation coefficients and a priori-specified hypotheses for the strength of associations. Results Of 60 participants, 48 were female, with a mean [standard deviation, ± SD] age of 62.6 ± 9.96 and median disease duration of 15.49 (interquartile range 6–20.5) years. Theoretically consistent associations confirming construct validity [95% CI] were observed between the RADAI-F5 and MSUS GS (0.76 [0.57-0.82]; strong), MSUS PD (0.55 [0.35-0.71]; moderate), MSUS-detected erosions (0.41 [0.18-0.61]; moderate), clinical tenderness (0.52 [0.31-0.68]; moderate), and clinical swelling (0.36 [0.13-0.55]; weak). Conclusion Moderate-to-strong correlations between RADAI-F5 and MSUS demonstrate this instrument's good measurement properties. With greater confidence in the utility of the RADAI-F5, clinical use of this novel instrument as an adjunct to the DAS-28 could help identify RA patients at risk for poor functional and radiological outcomes. Lay summary What does this mean for patients? Rheumatoid arthritis (RA) is a condition that commonly affects the feet. It is important to have a reliable way to measure the activity of RA in the feet. One such measure is called the Rheumatoid Arthritis Foot Disease Activity Index (RADAI-F5), which is a five item questionnaire completed by patients. However, the RADAI-F5 still needs to be validated against other methods of assessing foot disease activity, such as musculoskeletal ultrasonography (MSUS) and clinical examination. In this study, 60 participants with RA were enrolled. Participants completed the RADAI-F5 questionnaire. Thereafter, MSUS was used to evaluate disease activity and joint damage in the participants' feet. Clinical examinations to assess swelling and tenderness were also conducted at this appointment. The results showed that there were strong-to-moderate consistent associations between the RADAI-F5 scores and MSUS grayscale images, MSUS Power Doppler and the presence of joint damage. The RADAI-F5 scores also correlated moderately with clinical tenderness and weakly with clinical swelling. These findings suggest that the RADAI-F5 is a reliable tool for measuring foot disease activity in RA patients. The tools implementation in clinical practice may help better identify RA patients who are at risk for poor outcomes and may require more targeted treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Assessing the construct validity of musculoskeletal ultrasound and the rheumatoid arthritis foot disease activity index (RADAI-F5) for managing rheumatoid foot disease

Hoque

Steultjens

Dickson

et al. 2023

Rheumatology Advances in Practice

View full text Add to dashboard Cite

show abstract

Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry

Duruöz,

Ataman,

Bodur

et al. 2023

Rheumatol Int

View full text Add to dashboard Cite

Interleukin-6 Suppression by Different TNF Inhibitors in Rheumatoid Arthritis Patients During Maintenance Therapy

Mohammed,

Saaed

2023

Al-Rafidain J Med Sci

View full text Add to dashboard Cite

in rheumatoid arthritis (RA). Objectives: To evaluate the effect of different TNF inhibitors on plasma IL-6 levels and disease activity in RA patients. Methods: A longitudinal, observational study included 65 adult RA patients receiving TNF inhibitors for at least six weeks in Sulaymaniyah, Iraq, between February and August 2022. Disease activity was assessed using the disease activity score 28 (DAS28). Plasma IL-6 levels, CRP, and ESR were measured at two time points over 14 weeks during maintenance therapy. Results: After 14 weeks, adalimumab lowered IL-6 levels to 31.92 ng/L (0.24), ESR to 15 mm/hr (16.8), and CRP to 8.4 mg/L (26.2). DAS28/ESR was also improved, it went from 4.7 (1.2) to 4.0 (1.3), which was the biggest change. Infliximab decreased IL-6 31.87 ng/L (0.29), ESR 10.1 mm/hr (15.0), and CRP 7 mg/L (13.5), but the smallest improvement was in DAS28/ESR 4.6 (1.6) to 4.5 (1.2). Etanercept exhibited the lowest decrease in IL-6, ESR, and CRP: 31.77 ng/L (0.39), 7.5 mm/hr (6.5), and 4.9 mg/L (4.9), respectively. However, it showed the second-greatest median improvement in DAS28/ESR, from 4·4 (1·8) to 4·0 (1·4). No correlation was found between plasma IL-6 levels and DAS28/ESR at either time point. Conclusion: TNF inhibitors differ in reducing plasma IL-6 levels and DAS28 during maintenance therapy in RA patients. Adalimumab was the most effective in reducing IL-6, CRP, ESR levels, and DAS28.

show abstract

Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis

Cited by 3 publications

References 37 publications

Assessing the construct validity of musculoskeletal ultrasound and the rheumatoid arthritis foot disease activity index (RADAI-F5) for managing rheumatoid foot disease

Assessing the construct validity of musculoskeletal ultrasound and the rheumatoid arthritis foot disease activity index (RADAI-F5) for managing rheumatoid foot disease

Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry

Interleukin-6 Suppression by Different TNF Inhibitors in Rheumatoid Arthritis Patients During Maintenance Therapy

Contact Info

Product

Resources

About